Login to Your Account



Clinic Roundup


Tuesday, May 29, 2012
• Summit Corp. plc, of Oxford, UK, dosed the first cohort of patients in a Phase I study of SMT C1100, a small-molecule utrophin up-regulator under investigation in Duchenne's muscular dystrophy (DMD).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription